04 April 2018 | News
Lasergen and Agilent have been collaborating on building a next-generation sequencing workflow for clinical applications.
Image credit- insaonline.org
Agilent Technologies Inc. and Lasergen, Inc. have signed a definitive agreement for Agilent to acquire the remaining shares of Lasergen, an emerging biotechnology company focused on research and development of innovative technologies for DNA sequencing, for $105 million.
Lasergen and Agilent have been collaborating on building a next-generation sequencing workflow for clinical applications, with sequencing technology based on Lasergen’s Lightning Terminators chemistry. Lightning Terminators offer potentially faster, more accurate and less expensive genome sequencing than other technologies currently on the market.
“Over the past two years, Agilent and Lasergen have worked closely together and developed a strong partnership,” said Kamni Vijay, Ph.D., vice president and general manager of Agilent’s Genomics division. “The decision to acquire the remaining shares of Lasergen demonstrates our commitment to the team and technology, and our strategic intent to build a complete routine clinical NGS workflow.”
In March 2016 Agilent made an initial investment in the privately-held company to acquire a 48-percent ownership stake with a two-year call option to acquire the remaining shares. Agilent gave its notice of exercise on February 23, 2018.